Novo Nordisk aktie (NOVO B) | Pressmeddelande

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

GlobeNewswire • 20 Dec 11:41

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, i...

GlobeNewswire • 18 Dec 14:59

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 16 Dec 13:52

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

GlobeNewswire • 16 Dec 07:29

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites fro...

GlobeNewswire • 14 Dec 06:08

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kid...

GlobeNewswire • 12 Dec 14:47

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Dec 16:43

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufactu...

GlobeNewswire • 06 Dec 19:11

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual mee...

GlobeNewswire • 03 Dec 14:00

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 02 Dec 12:46

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 25 Nov 16:16

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 19 Nov 14:33

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 18 Nov 16:08

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 13 Nov 17:18

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 12 Nov 20:00

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Nov 22:22

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 08 Nov 21:51

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

GlobeNewswire • 08 Nov 21:47

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Nov 15:07

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 07 Nov 18:27

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.

GlobeNewswire • 06 Nov 07:41

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.

GlobeNewswire • 06 Nov 07:30

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 05 Nov 14:37

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

GlobeNewswire • 01 Nov 13:13

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 28 Oct 13:11

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 21 Oct 14:50

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabete...

GlobeNewswire • 21 Oct 11:26

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with h...

GlobeNewswire • 18 Oct 11:32

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 14 Oct 14:06

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

GlobeNewswire • 08 Oct 10:00

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 07 Oct 12:44

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 30 Sep 13:02

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 23 Sep 13:56

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

GlobeNewswire • 20 Sep 14:43

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and ...

GlobeNewswire • 19 Sep 21:10

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 16 Sep 15:15

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Sep 16:10

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Sep 15:55

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 30 Aug 10:39

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 26 Aug 15:44

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 20 Aug 21:35

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 19 Aug 14:48

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 14 Aug 13:40

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 12 Aug 14:31

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 12 Aug 14:04

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 09 Aug 20:29

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Aug 18:54

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.

GlobeNewswire • 07 Aug 07:31

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 06 Aug 13:15

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 29 Jul 13:05

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardio...

GlobeNewswire • 25 Jul 17:08

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 22 Jul 14:22

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 15 Jul 12:50

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

GlobeNewswire • 10 Jul 23:45

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 08 Jul 15:18

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 01 Jul 15:19

Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

GlobeNewswire • 26 Jun 16:50

Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline

GlobeNewswire • 24 Jun 20:16

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 24 Jun 14:55

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatm...

GlobeNewswire • 23 Jun 07:01

Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th...

GlobeNewswire • 18 Jun 14:00

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 17 Jun 14:26

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 10 Jun 14:15

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 03 Jun 16:05

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 27 May 14:49

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 17 May 16:20

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 15 May 13:23

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and pr...

GlobeNewswire • 13 May 17:49

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 May 17:31

Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 06 May 21:02

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 06 May 20:44

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

GlobeNewswire • 06 May 20:40

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 03 May 19:48

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.

GlobeNewswire • 02 May 07:30

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 01 May 14:30

Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024

GlobeNewswire • 26 Apr 12:16

Novo Nordisk A/S - Articles of Association, April 2024

GlobeNewswire • 24 Apr 14:57

Novo Nordisk A/S – Reduction of the share capital

GlobeNewswire • 24 Apr 14:48

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 22 Apr 15:06

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 15 Apr 19:39

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 15 Apr 14:43

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 08 Apr 15:40

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 02 Apr 12:56

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 25 Mar 12:58

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

GlobeNewswire • 25 Mar 10:59

Novo Nordisk A/S - Articles of Association 2024

GlobeNewswire • 25 Mar 08:51

Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities

GlobeNewswire • 21 Mar 16:55

Resolutions from the Annual General Meeting of Novo Nordisk A/S

GlobeNewswire • 21 Mar 15:59

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 18 Mar 15:18

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 11 Mar 13:46

Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

GlobeNewswire • 08 Mar 19:42

Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024

GlobeNewswire • 07 Mar 08:00

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes ...

GlobeNewswire • 05 Mar 10:53

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 04 Mar 15:29

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 26 Feb 12:02

Notice for the Annual General Meeting of Novo Nordisk A/S

GlobeNewswire • 21 Feb 15:03

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 19 Feb 15:29

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 14 Feb 12:59

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 12 Feb 17:22

Börskollen

För dig med koll på börsen

Pressmeddelanden från Novo Nordisk

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Novo Nordisk A/S - share repurchase programme

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

Novo Nordisk A/S - share repurchase programme

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

Novo Nordisk A/S - share repurchase programme

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S – Share repurchase programme

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A

Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024